Personal information

No personal information available

Activities

Employment (3)

Leids Universitair Medisch Centrum: Leiden, Zuid-Holland, NL

2013-04-15 to present | senior post-doc (Medical Oncology)
Employment
Source: Self-asserted source
Saskia Santegoets

Amsterdam UMC Locatie VUmc: Amsterdam, Noord-Holland, NL

2007-10 to 2013-04-14 | post-doc (Medical Oncology)
Employment
Source: Self-asserted source
Saskia Santegoets

Amsterdam UMC Locatie VUmc: Amsterdam, Noord-Holland, NL

2001-10 to 2007-10 | PhD student (Pathology)
Employment
Source: Self-asserted source
Saskia Santegoets

Education and qualifications (2)

Vrije Universiteit Amsterdam: Amsterdam, Noord-Holland, NL

1999-09 to 2001-08 | MS
Education
Source: Self-asserted source
Saskia Santegoets

University of Applied Sciences Utrecht: Utrecht, NL

1995-09 to 1999-08 | BS
Education
Source: Self-asserted source
Saskia Santegoets

Works (50 of 58)

Items per page:
Page 1 of 2

The Tumor Microenvironment and Immunotherapy of Oropharyngeal Squamous Cell Carcinoma.

Frontiers in oncology
2020-12-21 | Journal article
Source: Self-asserted source
Saskia Santegoets

CD39 Identifies the CD4<sup>+</sup> Tumor-Specific T-cell Population in Human Cancer.

Cancer immunology research
2020-08-05 | Journal article
Source: Self-asserted source
Saskia Santegoets

CD163<sup>+</sup> cytokine-producing cDC2 stimulate intratumoral type 1 T cell responses in HPV16-induced oropharyngeal cancer.

Journal for immunotherapy of cancer
2020-08-01 | Journal article
Source: Self-asserted source
Saskia Santegoets

Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer.

Oncotarget
2020-06-02 | Journal article
Source: Self-asserted source
Saskia Santegoets

Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study.

Journal for immunotherapy of cancer
2020-03-01 | Journal article
Source: Self-asserted source
Saskia Santegoets

High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status.

Journal for immunotherapy of cancer
2019-09-03 | Journal article
Source: Self-asserted source
Saskia Santegoets

Correction to: Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial.

Cancer immunology, immunotherapy : CII
2019-06-01 | Journal article
Source: Self-asserted source
Saskia Santegoets
grade
Preferred source (of 2)‎

Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial.

Cancer immunology, immunotherapy : CII
2019-03-09 | Journal article
Source: Self-asserted source
Saskia Santegoets
grade
Preferred source (of 2)‎

Tbet-positive regulatory T cells accumulate in oropharyngeal cancers with ongoing tumor-specific type 1 T cell responses.

Journal for immunotherapy of cancer
2019-01-18 | Journal article
Source: Self-asserted source
Saskia Santegoets

Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.

Journal for immunotherapy of cancer
2019-01-15 | Journal article
Source: Self-asserted source
Saskia Santegoets

NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.

Cell
2018-11-29 | Journal article
Source: Self-asserted source
Saskia Santegoets

The Anatomical Location Shapes the Immune Infiltrate in Tumors of Same Etiology and Affects Survival.

Clinical cancer research : an official journal of the American Association for Cancer Research
2018-09-17 | Journal article
Source: Self-asserted source
Saskia Santegoets

EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer.

PloS one
2018-09-07 | Journal article
Source: Self-asserted source
Saskia Santegoets

A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia.

Cancer immunology, immunotherapy : CII
2018-07-23 | Journal article
Source: Self-asserted source
Saskia Santegoets

The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival.

Oncoimmunology
2018-05-31 | Journal article
Source: Self-asserted source
Saskia Santegoets

Intratumoral HPV16-Specific T Cells Constitute a Type I-Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research
2017-10-10 | Journal article
Source: Self-asserted source
Saskia Santegoets

Immunological effects of everolimus in patients with metastatic renal cell cancer.

International journal of immunopathology and pharmacology
2017-10-09 | Journal article
Source: Self-asserted source
Saskia Santegoets

Monitoring of the Immune Dysfunction in Cancer Patients.

Vaccines
2016-09-02 | Journal article
Source: Self-asserted source
Saskia Santegoets

Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses.

Science translational medicine
2016-04-01 | Journal article
Source: Self-asserted source
Saskia Santegoets

Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node.

Cancer immunology, immunotherapy : CII
2016-03-02 | Journal article
Source: Self-asserted source
Saskia Santegoets

Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells.

Oncoimmunology
2015-12-21 | Journal article
Source: Self-asserted source
Saskia Santegoets

A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.

Oncotarget
2015-10-01 | Journal article
Source: Self-asserted source
Saskia Santegoets

A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology
2015-07-27 | Journal article
Source: Self-asserted source
Saskia Santegoets

Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry.

Cancer immunology, immunotherapy : CII
2015-06-28 | Journal article
Source: Self-asserted source
Saskia Santegoets

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab.

Journal for immunotherapy of cancer
2014-09-16 | Journal article
Source: Self-asserted source
Saskia Santegoets

The Thirteenth International Conference on Progress in Vaccination Against Cancer (PIVAC-13), October 2-4, 2013, Amsterdam, The Netherlands: the current standing of anti-tumor immunotherapeutic approaches.

Cancer immunology, immunotherapy : CII
2014-03-12 | Journal article
Source: Self-asserted source
Saskia Santegoets

IL-10 conditioning of human skin affects the distribution of migratory dendritic cell subsets and functional T cell differentiation.

PloS one
2013-07-18 | Journal article
Source: Self-asserted source
Saskia Santegoets

Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients.

Journal of translational medicine
2013-06-20 | Journal article
Source: Self-asserted source
Saskia Santegoets

IL-21 in cancer immunotherapy: At the right place at the right time.

Oncoimmunology
2013-04-16 | Journal article
Source: Self-asserted source
Saskia Santegoets

Functional characterization of a STAT3-dependent dendritic cell-derived CD14<sup>+</sup> cell population arising upon IL-10-driven maturation.

Oncoimmunology
2013-04-01 | Journal article
Source: Self-asserted source
Saskia Santegoets

Priming of PRAME- and WT1-specific CD8<sup>+</sup> T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapy.

Oncoimmunology
2013-04-01 | Journal article
Source: Self-asserted source
Saskia Santegoets

IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells.

Journal of translational medicine
2013-02-12 | Journal article
Source: Self-asserted source
Saskia Santegoets

Increased cytotoxic capacity of tumor antigen specific human T cells after in vitro stimulation with IL21 producing dendritic cells.

Human immunology
2013-01-29 | Journal article
Source: Self-asserted source
Saskia Santegoets

Transcriptional profiling of human dendritic cell populations and models--unique profiles of in vitro dendritic cells and implications on functionality and applicability.

PloS one
2013-01-14 | Journal article
Source: Self-asserted source
Saskia Santegoets

T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.

Cancer immunology, immunotherapy : CII
2012-08-10 | Journal article
Source: Self-asserted source
Saskia Santegoets

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

The Lancet. Oncology
2012-02-10 | Journal article
Source: Self-asserted source
Saskia Santegoets

An α-galactosylceramide nose job shapes up iNKT cells.

Immunotherapy
2012-01-01 | Journal article
Source: Self-asserted source
Saskia Santegoets

Bulldozing β-linked glycolipids for recognition by invariant NKT cells.

Immunotherapy
2012-01-01 | Journal article
Source: Self-asserted source
Saskia Santegoets

Gram-positive bacteria: a major microbial ‘turn-on’ for invariant NKT cells.

Immunotherapy
2012-01-01 | Journal article
Source: Self-asserted source
Saskia Santegoets

Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.

BMC cancer
2011-11-30 | Journal article
Source: Self-asserted source
Saskia Santegoets

Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α.

Clinical immunology (Orlando, Fla.)
2011-11-04 | Journal article
Source: Self-asserted source
Saskia Santegoets

Research resource: transcriptome profiling of genes regulated by RXR and its permissive and nonpermissive partners in differentiating monocyte-derived dendritic cells.

Molecular endocrinology (Baltimore, Md.)
2010-09-22 | Journal article
Source: Self-asserted source
Saskia Santegoets

Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus.

Journal of immunotherapy (Hagerstown, Md. : 1997)
2010-09-01 | Journal article
Source: Self-asserted source
Saskia Santegoets

4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes.

Clinical immunology (Orlando, Fla.)
2010-08-13 | Journal article
Source: Self-asserted source
Saskia Santegoets

Impact of varicella-zoster virus on dendritic cell subsets in human skin during natural infection.

Journal of virology
2010-02-03 | Journal article
Source: Self-asserted source
Saskia Santegoets

Mutz-3-derived Langerhans cells are a model to study HIV-1 transmission and potential inhibitors.

Journal of leukocyte biology
2009-12-30 | Journal article
Source: Self-asserted source
Saskia Santegoets

CXCL12 is essential for migration of activated Langerhans cells from epidermis to dermis.

European journal of immunology
2008-11-01 | Journal article
Source: Self-asserted source
Saskia Santegoets

Human dendritic cell line models for DC differentiation and clinical DC vaccination studies.

Journal of leukocyte biology
2008-07-29 | Journal article
Source: Self-asserted source
Saskia Santegoets

Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients.

Clinical cancer research : an official journal of the American Association for Cancer Research
2008-07-01 | Journal article
Source: Self-asserted source
Saskia Santegoets

The novel bispecific diabody alphaCD40/alphaCD28 strengthens leukaemic dendritic cell-induced T-cell reactivity.

British journal of haematology
2008-05-19 | Journal article
Source: Self-asserted source
Saskia Santegoets
Items per page:
Page 1 of 2